Definitive Healthcare (NASDAQ:DH) Updates FY 2026 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) updated its FY 2026 earnings guidance on Monday morning. The company provided earnings per share guidance of 0.180-0.200 for the period, compared to the consensus estimate of 0.160. The company issued revenue guidance of $220.0 million-$222.0 million, compared to the consensus revenue estimate of $223.6 million. Definitive Healthcare also updated its Q3 2026 guidance to 0.040-0.050 EPS.

Definitive Healthcare Stock Down 7.8%

Shares of DH opened at $0.64 on Wednesday. The firm has a 50 day simple moving average of $0.77 and a two-hundred day simple moving average of $1.10. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.75 and a quick ratio of 1.75. Definitive Healthcare has a one year low of $0.62 and a one year high of $4.35. The company has a market cap of $67.92 million, a P/E ratio of -0.40, a P/E/G ratio of 11.27 and a beta of 1.35.

Definitive Healthcare (NASDAQ:DH) last announced its quarterly earnings data on Monday, August 10th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.01. The business had revenue of $55.20 million during the quarter, compared to the consensus estimate of $55.47 million. Definitive Healthcare had a positive return on equity of 3.18% and a negative net margin of 77.00%.Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. Research analysts forecast that Definitive Healthcare will post 0.04 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on DH. Zacks Research upgraded Definitive Healthcare from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. Robert W. Baird set a $1.10 price target on Definitive Healthcare in a research report on Friday, May 8th. Wall Street Zen raised Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Sunday, July 26th. Morgan Stanley cut their price objective on Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating on the stock in a research note on Tuesday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Definitive Healthcare in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, four have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $1.55.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. raised its holdings in shares of Definitive Healthcare by 564.2% during the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock valued at $25,191,000 after purchasing an additional 7,404,363 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Definitive Healthcare by 1.6% in the third quarter. Dimensional Fund Advisors LP now owns 2,073,197 shares of the company’s stock worth $8,417,000 after acquiring an additional 33,612 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Definitive Healthcare by 11.7% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,216,007 shares of the company’s stock valued at $4,937,000 after acquiring an additional 127,055 shares in the last quarter. Bank of America Corp DE raised its position in shares of Definitive Healthcare by 23.7% during the second quarter. Bank of America Corp DE now owns 769,397 shares of the company’s stock worth $3,001,000 after purchasing an additional 147,599 shares during the period. Finally, Inspire Investing LLC lifted its holdings in shares of Definitive Healthcare by 505.7% in the 4th quarter. Inspire Investing LLC now owns 698,967 shares of the company’s stock worth $2,006,000 after purchasing an additional 583,562 shares in the last quarter. 98.67% of the stock is owned by institutional investors.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.